Outcome of Board meeting for Financial Results

Pat NegativeEbitda Margin CompressionExceptional ItemEmphasis Of MatterResults View source PDF

AKUMS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

-4.3%1-day move

₹540.00

prior close

₹544.00

base price

In-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

-2.2-4.0-4.2-1.7-4.3-4.8-3.7-5.1-3.1-3.5+2.4+14.6+27.2—

Up moveDown movePending

AI summary

Akums Drugs reported standalone PAT of ₹1,116.40 million for FY2026, down 30.7% from ₹1,609.98 million in FY2025. Revenue from operations grew marginally to ₹13,487.36 million from ₹13,117.84 million. The auditors issued an unmodified opinion but included an Emphasis of Matter regarding an Income Tax Department search and seizure operation (January 2025) and subsequent show cause notices, with impact not yet ascertainable. Exceptional items of ₹65.19 million were recognized due to changes in labour code and retrospective VDA arrears. The Board recommended a final dividend of ₹1 per share plus a special dividend of ₹2 per share. Changes in senior management were also approved.

Likely market impact

The significant PAT decline of ~31% despite marginal revenue growth signals margin compression and operational challenges. The unresolved Income Tax Department proceedings create regulatory uncertainty. The special dividend suggests management confidence, but investors should monitor the tax investigation outcome.